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Summary 
VIP is a peptide hormone capable of activating the cAMP/PKA pathway and modifying 
gonadal steroidogenic capacity. Less is known about the molecular mechanisms of VIP-
mediated steroidogenesis and its role in regulating the steroidogenic acute regulatory protein 
(STAR). We examined the impact of VIP on STAR expression and function in immortalized 
(KK1) and primary mouse granulosa cells, where VIP strongly upregulated STAR expression 
and steroidogenesis. Inhibitors of the PKA and PKC pathways suggested that both are 
activated by VIP. VIP did not efficiently phosphorylate STAR (P-STAR); however, VIP 
together with cAMP-analogs that activate Type II PKA increased P-STAR and further 
increased steroidogenesis. Our results suggest that VIP-induced STAR expression and 
function in granulosa cells result from the preferential activation of Type I PKA. Furthermore, 
the PKA and PKC pathways appear to converge at regulating VIP-mediated Star transcription 
and translation. 
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Introduction 
Vasoactive intestinal peptide (VIP) is a 28-amino acid molecule located in multiple tissues, 
and capable of exerting a variety of biological effects, including well documented 
neuroendocrine actions (Abe et al., 1985; Lopez et al., 1989). One of them is the function of 
VIP as a physiological PRL-releasing factor of pituitary origin (Abe et al., 1985).  
In the female genital tract the localization of VIP immunoreactive nerves have been described 
in association with the smooth muscles of blood vessels and the uterus, as well as with the 
ovarian stroma (Larsson et al., 1977; Alm et al., 1980; Huslhof et al., 1994). In bovine 
granulosa cells, immunohistochemical signals for VIP increased in the growing and 
preovulatory follicles that were coincident with the LH-peak suggesting a role for VIP in the 
final stages of follicle development and ovulation (Hulshof et al., 1994). This is in accordance 
with the findings of Schmidt et al., 1990, who reported on the increased number of in-vitro 
ovulations with VIP-perfused ovaries from PMSG primed rats.  
Within the ovary, VIP is involved in the regulation of steroidogenic activity, stimulating 
estradiol and progesterone production in cultured granulosa cells (Davoren and Hsueh, 1985; 
Ahmed et al., 1986; Parra et al., 2007). At the same time VIP decreases activity of 20αHSD in 
these cells, and thus supports the biological activity of progesterone by decreasing the rate of 
its metabolism to biologically inactive 20α-OH-progesterone (Davoren and Hsueh, 1985).  
In the periphery, the denervation of ovaries during the early luteal phase of the estrus cycle 
leads to changes in their morphology and impairs steroidogenic activity in pigs (Jana et al., 
2005). Similarly, inhibition of ovarian secretory function and delayed pubertal onset were 
observed in rats after denervation (Ojeda et al., 1983; Lara et al., 1990; Forneris et al., 2002). 
The alterations in gonadal endocrine function are attributed to the loss of the peptidergic 
supply of neuronal fibers (Jana et al., 2005; Ojeda et al., 1983; Lara et al., 1990; Forneris et 
al., 2002). 
The biological action of VIP is mediated through two G-coupled receptors designated as 
VIPR1 and -2 (respectively, VIPAC-1 and VIPAC-2) (Vaudry et al., 2000). Both receptors 
are expressed in the ovaries of different species (Hulshof et al., 1994; Vaccaris et al., 2006; 
Bao et al., 2000; Cecconi et al., 2004). Acting through its receptors, VIP dose-dependently 
increases intracellular cAMP content (Robberecht et al., 1979) and subsequently leads to 
protein kinase A (PKA) activation, which in turn induces steroidogenesis in granulosa cells. 
Nevertheless, the molecular mechanisms by which VIP induces steroidogenesis, and 
specifically VIP’s role in regulating STAR expression, remain unclear. STAR mediates the 
rate-limiting step in steroidogenesis, the transfer of cholesterol from the outer to the inner 
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mitochondrial membrane, and it is the hormonal regulation of STAR expression and activity 
that allows tissues to accurately control their steroid production. The cAMP/PKA pathway is 
the major route in the trophic hormone-stimulated regulation of STAR expression and 
function, and both known subtypes of PKA (type I and type II) are present in steroidogenic 
tissues. In mouse Leydig tumor cells, type I PKA is more responsible for Star gene 
expression, while type II PKA impacts the post-translational regulation of STAR by more 
readily phosphorylating newly synthesized STAR protein (Dyson et al., 2009). Moreover, 
VIP may affect steroid production through mechanisms downstream of STAR. Recently, a 
reduction of STAR and 3β-hydroxysteroid dehydrogenase (3βHSD; enzyme converting 
pregnenolone to progesterone) expression accompanied by decreased serum levels of FSH 
was demonstrated in young VIP knockout mice (Lacombe et al., 2007).  
These findings, together with the previously reported decrease in gonadal secretory function 
after neurectomy, strongly suggest an important role for the peptidergic supply from the 
peripheral neuronal system, and in particular for VIP, in regulating STAR-mediated 
steroidogenesis in the gonad. In order to address this hypothesis in the present study we used 
VIP to examine the molecular mechanisms involved in the VIP-mediated regulation of STAR 
expression in immortalized (KK1) and primary mouse granulosa cells.  
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Material and Methods 
Chemicals and Reagents 
N6,2-dibutyryladenosine-3,5-cyclic monophosphate (dbcAMP), phorbol 12-myristate 13-
acetate (PMA), H89, pregnant mare serum gonadotropin (PMSG; Gonadotropin), Triton X-
100 (TX-100), protease inhibitor cocktail, high glucose (4.5g/l) Dulbecco’s modified Eagle’s 
medium (DMEM) and F12 medium and recombinant VIP were purchased from Sigma-
Aldrich (St. Loius, MO).  
PKC-specific inhibitor GF-10923X (GFX) was obtained from AG Scientific (San Diego, CA, 
USA). 8-Piperidinoadenosine-3’, 5’-cyclic monophosphate (PIP-cAMP) and N6-mono-tert-
butylcarbamoyl-adenosine-3’, 5’-cyclic monophosphate (MBC-cAMP) were purchased from 
BioLog (Bremen, Germany). Tissue culture-grade antibiotics, TRIzol, PCR primers, trypsin 
EDTA and PBS were purchased from Invitrogen (Carlsbad, CA). The 6-carboxyfluorescein 
(6-FAM) and 6-carboxytetramethyl-rhodamine (TAMRA) labelled probes (TaqMan Probes) 
were from Eurogentec, North America (San Diego, CA). Fetal bovine serum (FBS) was from 
Life Technologies Inc. (Gaithersburg, MD). TaqMan Reverse Transcription Reagents® were 
from Applied Biosystems (Foster City, CA). Fast Start Universal Probe Master (ROX)®, 
DNase I recombinant, RNase-free and FuGENE HD transfection reagent were purchased 
from Roche Diagnostics (Indianapolis, IN). The PaphDetect® in Vivo Signal Transduction 
Pathway trans-Reporting System was from Stratagene (La Jolla, CA). The dual-luciferase 
reporter assay system was from Promega Corp., Madison, WI. 
 
Primary granulosa cells 
Primary granulosa cells were obtained from mature, female CD-1 strain mice (Charles River, 
Wilmington, MA; donated by Dr. GA Cornwall from the Department of Cell Biology and 
Biochemistry, Texas Tech University Health Sciences Center, Lubbock). Animals were 
housed under a constant 12L:12D photoperiod and were allowed free access to food and 
water. Experiments were carried out in accordance with the principles and procedures 
described in the NIH Guidelines for Care and Use of Experimental Animals. Mice were killed 
by cervical dislocation 48h after an ip injection of 8 IU PMSG. A previously described 
protocol for primary granulosa cell isolation (Salustri et al., 1985) was used. Briefly, the 
ovaries were removed, trimmed of the surrounding tissue and placed in a HEPES-buffered 
culture DMEM/F12 (1:1) medium containing heat inactivated 10% FBS, 100 U/ml penicillin 
and 100 µg/ml streptomycin. The largest follicles were punctured under a dissecting 
microscope control and cumuli oophori and granulosa cells were released in the medium. 
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Ovarian remnants and cumuli oophori were removed and cells were washed twice in the 
medium with centrifugation steps in between (600 X g, 10 min). After final centrifugation 
cells were resuspended in culture medium. Cell number and viability were assessed by trypan 
blue (0.5%) staining and hemocytometer counting. Cells were seeded in 6-well plates at a 
density of 2x106 cells per well and used for experiments 24 hrs later. 
 
Cell culture and Radioimmunoassay 
Immortalized KK1 mouse granulosa cells (kindly provided by Dr. Ilpo Huhtaniemi, 
Hammersmith Campus, Imperial College London, London UK) and primary granulosa cells 
were cultured in a humified incubator at 37°C and 5% CO2. KK1 cells were maintained in 
HEPES-buffered DMEM/F12 (1:1) medium containing 10% heat inactivated FBS, 100 U/ml 
penicillin and 100 µg/ml streptomycin. 24hrs prior to stimulation experiments cells were 
seeded in 6-well plates. For stimulation experiments, cells grown to 70-80% confluency were 
washed with PBS in order to remove the serum-containing media, which was then replaced by 
serum-free media containing the agonists. For all experiments cells were stimulated over the 
time period of 6 hrs. This time point have been chosen based on preliminary experiments in 
which the highest STAR levels, P-STAR and progesterone output were observed (not shown). 
For the experiments were the time course of VIP-mediated PKA activity and CREB and cJUN 
phosphorylation are presented, 4h time-span has been shown since PKA activity started to 
decrease after 30 min, reaching basal level after 120 min. This was accompanied by the P-
cJUN decrease; CREB remained phosphorylated over the entire observation time period. 
Finally the medium was collected and stored at -20°C for subsequent radiommunoassay 
(RIA). The concentration of progesterone was assayed as previously described (Resko et al., 
1974) and expressed as pg of progesterone per µg of protein. 
 
Luciferase Assays 
The -151/-1 bp fragment of the Star-promoter cloned upstream of the Firefly luciferase 
reporter gene in the pGL2 basic vector (Promega Corp., Madison, WI) was used for the 
reporter assay as previously reported (Manna et al., 2002). 24 hrs before transfection KK1 
cells were seeded in 6-well plates and then transfected using FuGENE HD transfection 
reagent as described in Kowalewski et al., 2009. 1µg of Star-promoter plasmid DNA was 
used per well. pRL-SV40 plasmid expressing Renilla luciferase driven by CMV immediate-
early enhancer and promoter was used to normalize for the transfection efficiency. The 
activity of the -151/-1 bp Star-promoter construct in response to the VIP and/or dbcAMP 
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treatment was determined after 6 hrs of incubation. The dual-luciferase reporter system was 
used according to the manufacturer’s instructions (Promega). Luminescence was measured 
using TD-20/20 luminometer (Turner Designers, Sunnyvale, CA). Promoter activity in the 
samples is reported in relative light units (RLU) and expressed as the ratio of Firefly 
luciferase luminescence to that of Renilla luciferase.  
 
Protein preparation and Western blot analyses 
Following treatments, whole cell lysates were prepared with NET-2 lysis buffer (50 mM Tris-
HCl [pH 7.4], 300 mM NaCl, 0.05% NP-40; Ishigaki et al., 2001) containing 10 µl/ml 
protease inhibitor cocktail (Sigma Aldrich). Cells were homogenized by sonication with three 
10s pulses using a Tekmar TK300 sonic disruptor (Tekmar, Cincinnati, OH). After 
centrifugation at 10,000xg for 10 min at 4°C the supernatants were used for SDS-PAGE as 
previously described (Manna et al., 2002). 
Primary antibodies were obtained from the following sources: rabbit antiserum generated 
against STAR protein, was a gift from Dr. W.L. Miller (Department of Pediatrics, University 
of California, San Francisco, CA; Bose et al., 1999); antiserum against the phosphorylated 
STAR (phospho-STAR) was a gift from Dr. Steven King (Scott Department of Urology, 
Baylor College of Medicine, Houston, TX); CREB (48H2) rabbit mAb, phospho-CREB 
(Ser133) mouse mAb and phospho-c-JUN (Ser63) II rabbit antibody were from Cell Signaling 
Technology Inc. (Danvers, MA); rabbit polyclonal c-JUN (H-79; sc-1694) and GAPDH (sc 
47724) mouse monoclonal antibodies were purchased from Santa Cruz Biotechnology, (Santa 
Cruz, CA); mouse anti VIPR1 mAB and mouse anti VIPR2 mAb were from Millipore 
Corporation, USA; Rabbit anti-CYP11A1 (P450scc) antibody was from Chemicon 
(Temecula, CA); rabbit anti 3βHSD antiserum was from….. Secondary HRP donkey anti-
rabbit IgG and SuperSignal West chemiluminescent substrates were obtained from Pierce 
Biotechnology (Rockford, IL). Anti-mouse IgG conjugated to HRP was obtained from 
Promega Corp., Madison, WI.  
 
RNA extraction and semi-quantitative Real Time PCR 
Semi-quantitative Real Time (TaqMan) PCR was carried out in an automated fluorometer 
ABI PRISM® 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) 
according to a previously described protocol (Kowalewski et al., 2006). Briefly, total RNA 
was isolated using TRIzol ® -Reagent and treated with DNase for the elimination of genomic 
DNA-contamination. Reverse transcription reagents for TaqMan, obtained from Applied 
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Biosystems, were used with100 ng of DNase-treated total RNA for each sample. Samples 
were run in duplicates using Fast Start Universal Probe Master (ROX)® from Roche 
Diagnostics. Amplification conditions were as follows: initial denaturation at 95oC for 10 min 
followed by 40 cycles: 95oC for 15 s, 60oC for 60 s. Specificity of selected PCR products was 
confirmed by sequencing (Experimental Sciences Building, Texas Tech University, Lubbock, 
TX).  
Relative quantification was performed using the comparative CT method (ΔΔ CT method), 
according to the instructions of the manufacturer of the ABI PRISM™ 7000 Sequence 
Detector and as described in Kowalewski et al., 2006. Results of the Real Time PCR are 
expressed as the fold-change in gene expression over the non-treated controls. 
Sequences for primers and TaqMan probes used for detection of Star and GAPDH cDNAs 
were as follows: 
Star (forward): 5´-CCG GGT GGA TGG GTC AA-3´ 
Star (reverse): 5´-CAC CTC TCC CTG CTG GAT GTA-3´ 
Star (TaqMan Probe): 5´-CGA CGT CGG AGC TCT CTG CTT GG-3´ 
Gapdh (forward): 5´- GCA GTG GCA AAG TGG AGA TTG-3´ 
Gapdh (reverse): 5´-GTG AGT GGA GTC ATA CTG GAA CAT G -3´ 
Gapdh (TaqMan Probe): 5´-TCA ACG ACC CCT TCA TTG ACC TC -3´ 
 
PathDetect® c-JUN Trans-Reporting Systems  
KK1 cells were transfected with cJUN signal transduction pathway trans-reporting systems 
(Strategene, La Jolla, CA) according to the manufacturer’s protocol and as described in 
Kowalewski et al., 2009. 36 hrs after transfection cells were stimulated for 6 h with VIP 
and/or cAMP and the luciferase activity in the cell lysates was determined using a TD 20/20 
luminometer (Turner Designs). 
 
PKA activity 
The levels of PKA activity after treatment with VIP in KK1 cells were determined with the 
SignaTECT PKA assay system (Promega) as described in Dyson et al., 2008. 
 
Data analysis and Statistics 
All experiments were independently repeated at least 3 times. Shown are the representative 
Western blots for each experiment. The experiments utilizing Luciferase Reporter Assays and 
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Real Time PCR were performed at least three times in duplicate. Statistical data are expressed 
as the fold change relative to the non-treated controls. A parametric one-way analysis of 
variance (ANOVA) followed by Dunnett’s Multiple Comparison Test was applied with the 
statistical software program, GraphPad 3.06 (GraphPad Software, Inc, San Diego, CA, USA). 
Numerical data were presented as the mean ± standard deviation. 
 
 
Results 
Role of VIP on STAR, 3β-hydroxysteroid dehydrogenase, P-450scc expression and steroid 
production in granulosa cells. 
Using western blot analysis, the expression of both VIP receptors (VIPR1 and VIPR2) was 
detected in the KK1 cells indicating that these cells can potentially respond to VIP stimulation 
(Fig. 1A). In untreated KK1 cells STAR could be detected, but very little progesterone was 
synthesized over 6h. When treated with 0.1 µM - 2µM VIP for 6 h, KK1 cells demonstrated a 
dose-dependent increase in STAR protein and progesterone synthesis (Fig 1B,C). Total STAR 
increased by approximately 2.2-fold (p<0.05) when treated with 0.1 µm VIP and was further 
elevated up to 3-fold (p<0.01) with 2.0 µm VIP. Progesterone concentration in the media was 
elevated by 2.3-, 3.2- and 4-fold with 0.1 µM, 1 µM and 2µM VIP, respectively (p<0.01) and 
was lower than expected given the very significant increase in total STAR protein expression. 
Stimulation of KK1 cells with VIP in the presence of 0.3 mM dbcAMP further increased total 
STAR expression and steroid output, which was enhanced by 60% in the co-treatment 
experiments (Fig. 1B,C) if compared to the groups treated with VIP alone. Total STAR 
increased up to 4.71-fold (p<0.01) and steroid production was elevated by 6.43-fold (p<0.01) 
over non-treated controls (Fig. 1B,C). No P-STAR was detected when 0.1 µM VIP was used 
to stimulate the cells. STAR protein was only weakly phosphorylated (P-STAR) (and hence 
activated) when cells were treated with 1.0 µM VIP, and somewhat stronger phosphorylation 
was observed with 2.0 µM VIP. Addition of dbcAMP to VIP-treated cells synergistically 
phosphorylated and thus activated STAR (Fig. 1C). To determine whether VIP affected Star 
gene expression, semi-quantitative Real Time PCR and experiments examining Star promoter 
activity were performed. Treatment with 0.1 µM VIP significantly elevated Star mRNA by 
13.93-fold (p<0.01) over untreated cells, and maximal values corresponding to 16.52- and 
17.52-fold induction were reached with 1.0- and 2.0 µM VIP, respectively (Fig. 2A). 
Treatment with 0.3 dbcAMP also increased Star expression to similar levels, but 
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quantitatively similar results were obtained when VIP was used individually or in co-
treatment with cAMP (Fig. 2C). Similarly, when the proximal -151/-1 bp Star reporter 
construct was transfected into KK1 cells, promoter activity displayed an approximately 3-fold 
(p<0.01) increase in response to VIP-treatment when compared with nontreated control (Fig. 
2B). This was comparable to effects observed after stimulation with 0.3 mM dbcAMP 
individually or in co-treatment (Fig. 2B). As seen with P450scc, the expression of 3βHSD 
was not significantly affected by VIP treatment either individually or in cotreatment with 
dbcAMP (Fig. 1C). 
To determine the physiological relevance of the VIP-mediated effects on STAR expression 
and steroidogenesis, granulosa cells isolated from PMSG-stimulated mice were analyzed 
using RIA and Real Time PCR (Fig. 3A,B). Treatment with 1µM VIP for 6 h resulted in a 
2.8-fold (p<0.01) increase in Star mRNA expression over untreated cells, and this increase 
closely resembled the induction seen after stimulation with 1mM dbcAMP (2.1-fold increase; 
p<0.01) (Fig. 3B). Accumulation of progesterone in the media was elevated by 8.9- (p<0.01) 
and 18.6-fold (p<0.01) by VIP and dbcAMP, respectively, when compared with controls, 
further confirming the involvement of VIP in the STAR-mediated steroidogenic response. 
These findings demonstrate that VIP is capable of strongly activating Star gene expression at 
levels similar to those observed with cAMP analog treatment. Notably, the VIP-mediated 
increase in Star mRNA did not correlate with a matched increase in steroid production as we 
observed in the group treated with dbcAMP. 
 
Effects of VIP on specific PKA activity. 
The levels of PKA activity following VIP stimulation were evaluated. To do this we 
examined the effect of 1 µM VIP on PKA activity in KK1 cells at different time points over a 
period of 4 h (Fig. 4A). PKA activity at the initial time point was very low; it rose steeply 
within the first 3 minutes, reaching a maximum after 15 minutes. After 30 minutes the PKA 
activity started to decrease reaching very low or basal values by 120 and 240 minutes. Cells 
treated with 1.0 mM dbcAMP were used as a positive control, and consistently yielded high 
PKA activity, even after 4-6 h of incubation. As a negative control for the assay, PKA activity 
was quenched with the PKA inhibitor H89.  
 
VIP-mediated effects on CREB and cJUN expression. 
Since VIP effectively induced Star gene and protein expression, it seemed plausible that 
transcription factors known to regulate Star transcription could be regulated by VIP. Using 
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Western blot analyses, we examined the expression and phosphorylation status of two 
prominent and well studied Star promoter activators that are sensitive to PKA: cJUN and 
CREB. KK1 cells were stimulated with 1µM VIP and changes in the phosphorylation status 
of both transcription factors were examined at different time points over a period of 4 h (Fig. 
4B). Both factors were readily detected in unstimulated cells, with no changes in total protein 
expression observed during the time course of the experiment. The relative abundance of 
phospho-CREB and phospho-cJUN were strongly induced following treatment with 1µM VIP 
when compared to total CREB and cJUN. The phosphorylation of cJUN (4-fold; p<0.01) 
occurred after 5 minutes, reached a maximum (4.9-fold; p<0.01) after 30 minutes of VIP 
stimulation, and started to decline afterwards, dropping to basal levels by 240 minutes 
(p>0.05) (Fig. 4B). The phosphorylation of CREB was significantly increased (2.6-fold; 
p<0.01) by 10 minutes, reaching a maximum (up to 5-fold) within 15 to 60 minutes and 
remaining high for the duration of the time course (Fig. 4B). Having seen the rapid 
phosphorylation of cJUN in response to VIP treatment, we assessed the functional activity of 
cJUN in response to these treatments. KK1 cells were transfected with a pathway-specific 
cJUN trans-reporting system. Cells were stimulated with 1mM dbcAMP and 1µM VIP either 
individually or in co-treatment for 6 h. A 1.55- (p>0.05) and 2.53-fold (p<0.01) increase in 
luciferase activity, relative to untreated controls, were observed in response to dbcAMP and 
VIP, respectively. A further, up to 3.12-fold increase (p<0.01), was detected in the groups 
treated with a combination of VIP and dbcAMP (Fig. 4C). These results reflect how VIP-
mediated activation of STAR expression and steroidogenesis could be coordinated by the 
targeted activation of the Star promoter and its transcriptional machinery. 
 
Role of PKA and PKC in VIP-mediated STAR expression and steroidogenesis. 
To more specifically evaluate the signalling events in VIP-mediated steroidogenesis, we 
wished to assess the independent roles of the PKA and PKC pathways as they function 
downstream of VIP, and to know how these pathways then affect STAR expression. To 
examine PKA, KK1 cells were treated with 0.3 mM dbcAMP and 1µM of VIP alone and in 
co-treatment. Cells pre-treated for 30 min with the specific inhibitor of PKA, H89 (20µM) 
markedly diminished (p<0.01) all responses (Fig. 5A,B,C). In order to elucidate the role of 
the PKC pathway in VIP-mediated steroidogenesis, StAR expression in response to the PKC 
activator, phorbol 12-myristate 13-acetate (PMA) was determined and compared with VIP. 
Stimulation of KK1 cells with 20 nM PMA resulted in a significant (p<0.01) increase in Star- 
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mRNA (6.3-fold; p<0.01) and protein (4.45-fold; p<0.01) expression (Fig. 6A,B). No P-
STAR and low steroid levels were observed in response to PMA (Fig. 76,C), corroborating 
the results of Jo et al., 2005, which were observed in mouse Leydig cells. The addition of 1 
µM VIP to PMA–treated cells enhanced total STAR, P-STAR and steroidogenesis when 
compared to cells treated with VIP alone (Fig. 6B,C). While VIP paired with PMA did result 
in increased P-STAR relative to the control and either compound alone, their combined use 
generated less P-STAR than 0.3 mM dbcAMP. Quantitatively similar levels of Star mRNA 
were observed in response to VIP and PMA (Fig. 6A). The inhibition of the PKC pathway by 
the specific inhibitor GF-109203X (GFX; 20 µM) markedly reduced the response to both 
PMA and VIP (Fig. 6). These findings demonstrate that signalling from not only PKA, but 
also PKC can transduce signals in response to VIP, and that these pathways converge to 
regulate STAR expression and function, and hence the steroidogenic response in these cells. 
 
The induction of STAR phosphorylation in response to vasoactive intestinal peptide (VIP); 
differential activation of PKA. 
The activation of PKC has been shown to result in the effective transcription and translation 
of STAR.  However, a further activation of the PKA pathway is required to effectively 
phosphorylate STAR and induce steroid production (Jo, et al., 2005). On the basis of this 
phenomenon, using specific analogs of cAMP to preferentially activate either type I or type II 
PKA, we were recently able to show that type I PKA is more involved in Star gene 
expression, while the activation of type II PKA is essential for efficient phosphorylation of 
STAR and consequently production of steroids (Dyson et al., 2009). Having observed the 
VIP-mediated effects predominantly in conjunction with Star gene activation and total STAR 
expression, we activated type II PKA (MBC-cAMP in combination with PIP-cAMP; Dyson et 
al., 2009) either alone or in conjunction with 0.1 µM – 1.0 µM VIP to demonstrate the impact 
of these treatments on STAR expression. The impact of the PKA analogs on the Star 
promoter was nominal when using 1 µM MBC-cAMP and 100 µM PIP-cAMP, 
concentrations previously demonstrated to preferentially activate type II PKA (Dyson et al., 
2009); neither STAR expression nor an increase in steroid production were observed in 
response to this treatment (Fig. 7B,C). As a positive control KK1 cells were treated with 0.3 
mM dbcAMP (Fig. 7). To demonstrate the specific activation of type II PKA, 20µM PMA 
was used either alone or in conjunction with type II analogs. As expected type II PKA 
activators resulted in the phosphorylation of PMA-induced STAR (Fig. 7B). As before, little 
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or no STAR phosphorylation was observed when KK1 cells were treated with up to 1.0 µM 
VIP. However, the addition of type II analogs resulted in phosphorylation of STAR to levels 
comparable with those observed in the group treated with PMA and type II activators and 
stimulated as much progesterone as in the cells treated with 0.3 mM cAMP (Fig. 7B,C). In 
this context the cAMP signalling from VIP appears to most directly affect type I PKA 
activity.  
 
Discussion 
The role of neuropeptides, and in particular VIP, in regulating gonadal steroidogenic activity 
has been widely discussed (Larsson et al., 1977; Alm et al., 1980; Davoren and Hsueh, 1985; 
El-Gehani et al., 1998a; Hulshof et al., 1994; Jana et al., 2005). All previous observations 
point towards an important role of peptidergic supply at the level of the peripheral neuronal 
system in regulating reproductive function. However, VIP is also capable of acting directly on 
the steroidogenic tissues of the gonads, where it effectively stimulates steroid production 
(Davoren and Hsueh, 1985; Ahmed et al., 1986; El-Gehani et al., 1998b; Parra et al., 2007). 
Even though there are some indications that VIP could be involved in STAR-mediated 
steroidogenesis (Lacombe et al., 2007), the role of VIP in this context has not been closely 
studied, much less fully elucidated. The present study extends our knowledge of the 
molecular regulatory mechanisms in which VIP acts to increase the steroidogenic response by 
driving STAR expression and function in immortalized mouse KK1 and primary mouse 
granulosa cells.  
Fitting with previous studies, we observed VIP to consistently induce steroidogenesis in 
granulosa cells in a concentration-dependent manner (Fig. 1B; Fig. 3A). This is in accordance 
with results reported by Davoren and Hsueh, 1985, where VIP dose-dependently stimulated 
progesterone and estrogen production in rat granulosa cells. Similarly, Parra et al., 1985 
observed increased steroid release from cultured ovarian tissue in response to stimulation with 
VIP. In addition, our current data demonstrate that VIP is capable of potently increasing the 
expression of STAR and steroid production both in KK1 and freshly isolated granulosa cells. 
Notably, VIP did not seem to regulate the enzymatic availability of P450scc and 3βHSD, 
since the expression of both enzymes were not significantly affected in response to VIP (Fig. 
1C).  
VIP acts through its two receptors, both of which are expressed in granulosa cells in vivo 
(Barberi et al., 2007) and which we also observed here in KK1 cells (Fig. 1A). As members of 
the secretin family of receptors, VIPR1 and VIPR2 are conventionally thought to activate 
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adenylate cyclase, and the activation of the VIPR leads to a dose-dependent increase in the 
intracellular cAMP content (Robberecht et al., 1979) that is potentially capable of increasing 
the PKA activity. Based on this, it is presumable that VIP would stimulate STAR expression 
via the PKA pathway. In our study, VIP proved to be a very potent activator of PKA. 
Maximal catalytic activity of the enzyme was reached within 15 minutes (Fig. 4A). During 
this time CREB and cJUN, two prominent factors in the Star transcriptional machinery were 
strongly phosphorylated (Fig. 4B), reflecting the targeted activation of Star gene expression in 
response to the peptidergic stimulation. This observation may mirror the pituitary, where 
previously published observations showed that VIP could strongly induce the phosphorylation 
of CREB (Fernandez et al., 2005). This data pairs well with the results from our real time 
PCR and promoter activity data indicating that incubation of KK1 and primary granulosa cells 
with VIP strongly induced Star promoter activity, resulting in mRNA levels comparable to 
those observed in response to dbcAMP. This suggests that cAMP signalling from VIP 
strongly enhances STAR expression at the transcriptional level. 
The activation of the PKA pathway is unquestionably the major signalling route in STAR-
mediated steroidogenesis. In this regard, the ability of VIP to activate the PKA pathway was a 
requirement for increases in STAR and steroidogenesis, since H89 diminished all VIP effects 
(Fig. 5). While it was clear that cAMP transduces signals from the activated VIPR in these 
cells, we noticed that STAR protein expression and steroidogenesis from VIP treatment 
lagged behind the transcription of Star. Notably, the lower doses of VIP consistently 
produced elevated Star promoter activity and Star mRNA levels that matched our dbcAMP 
controls, but STAR protein expression, phosphorylation and steroid production were typically 
lower even as VIP concentrations increased. This closely resembled the phenomenon 
described by Jo et al., 2005 regarding how PKC could regulate Star expression. Given that 
PKC and other signalling pathways can also be activated by VIP, we investigated the 
potential role of the PKC pathway in VIP mediated steroidogenesis. Blocking of PKC activity 
resulted in a significant reduction of the VIP response (Fig. 6), suggesting that PKC may also 
serve downstream of VIP. Additionally, the increased STAR expression and enhanced 
steroidogenic output in response to the combined treatment with VIP and PMA demonstrate 
an important role for PKC activity in mediating VIP effects. Thus, it appears that the 
cooperation between different signalling pathways is involved in the regulatory events in the 
VIP-mediated effects on STAR function and gonadal steroid production. 
Given that PKA activity was dramatically increased in these cells in response to VIP alone, 
and that Star was being actively synthesized, it was perplexing to observe reduced levels of 
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steroidogenesis. Specifically, increased levels of P-STAR and progesterone were observed 
when VIP was used in concert with dbcAMP. Thus VIP by itself, although capable of 
increasing STAR protein, did not permit effective phosphorylation of STAR, and resulted in 
lower steroidogenic output when compared to dbcAMP stimulation (Fig. 1B). This suggests 
that VIP requires further cAMP-mediated activation of PKA to produce a full response. 
Recently, we were able to illustrate how the different isoforms of PKA act in regulating 
STAR function (Dyson et al., 2009) with Type I PKA being more responsible for Star gene 
expression and Type II PKA appearing to be much more efficient at phosphorylating STAR.  
In view of these earlier reports, an interesting finding in our current study is the 
observations that the effects of VIP on STAR expression in granulosa cells may 
predominantly result from the preferential activation of type I PKA. We observed that VIP-
induced Star transcription and translation was supplemented by the additional activation of 
Type II PKA, which efficiently phosphorylated and hence activated STAR and consequently 
enhanced steroid production (Fig. 7). Similarly, in the experiments where PMA was used 
alone to activate PKC and induce Star expression, VIP was demonstrated to be a very potent 
activator of Star transcription. However, even when PMA and VIP were used together, P-
STAR levels were still lower than what we observed using dbcAMP, suggesting that some 
aspect of PKA signalling was still limited. Since the additional activation of type II PKA 
appeared sufficient to allow a full steroidogenic response to VIP treatment, we predict that 
VIPR cAMP signals are predominantly transduced through Type I PKA. Observations, such 
as the rapid and strong phosphorylation of CREB and cJUN in response to VIP make our 
hypothesis even more probable, since we have previously observed the phosphorylation of 
those two factors by type I PKA in MA10 mouse Leydig tumor cells (Dyson et al., 2009).  
The steroidogenic effects of VIP, though weaker than those seen with cAMP, could play a 
supportive role in trophic hormone regulated (e.g. FSH, LH) ovarian endocrine function. This 
becomes more plausible if the increased VIP immunoreactivity that has been seen in the 
bovine ovary immediately prior and during the LH-peak (Huslhof et al., 1994) is taken into 
account. Similarly the VIP concentration in the rat ovary is cycle stage dependent with the 
highest levels seen during dioestrus (Parra et al., 2007). 
In conclusion and as summarized in Fig. 8, our findings demonstrate that the capacity for VIP 
to induce steroidogenesis is mediated by PKA and PKC through STAR, and that these 
pathways appear to converge to regulate the levels of Star transcription and translation. 
Importantly, VIP induced STAR expression and function in granulosa cells most likely results 
from the preferential activation of Type I PKA in KK1 cells. Hence, VIP appears to be a 
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neuropeptide that is significantly involved in the regulation of steroidogenesis in granulosa 
cells. 
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Figures 
Figure 1: Expression of VIPR1 and VIPR2 and concentration-dependent increase in STAR 
expression and steroidogenic output in immortalized KK1 mouse granulosa cells treated with 
vasoactive intestinal peptide (VIP) against the background PKA activity. Cells were cultured 
in serum-free DMEM/F12 (1:1) medium with increasing concentrations of VIP with or 
without 0.3 mM dbcAMP for 6 h. A) Expression of VIPR1 and VIPR2 in KK1 control cells. 
B) Progesterone production in the collected media was determined by radioimmunoassay C) 
Cells were collected and homogenized, 20 µg of the lysate was used in western blot analysis 
of STAR (30 kDa), phospho (P)-STAR (30 kDa), 3β-hydroxysteroid dehydrogenase (3βHSD) 
(42 kDa), P450scc (45 kDa) and GAPDH (37 kDa). Protein expression was normalised 
against GAPDH; the average integrated optical density (IOD) for STAR and 3βHSD is shown 
as fold changes relative to the untreated control.  
 
Figure 2: Concentration-dependent increase in Star mRNA expression in immortalized KK1 
mouse granulosa cells treated with vasoactive intestinal peptide (VIP) against the background 
PKA activity. A) Star mRNA expression as determined by Real Time (TaqMan) PCR 
normalised against the GAPDH. One-way ANOVA with p < 0.0001 (A,B,C) followed by 
Dunnett’s multiple comparison test was applied; all samples were compared against the 
untreated control. (**) indicates p < 0.01 and (***) inicates p < 0.05. B) VIP increases Star 
promoter activity in immortalized KK1 mouse granulosa cells. Cells were transfected with -
151/-1 bp fragment of Star promoter subcloned to pGL2 vector containing Firefly luciferase 
as a reporter. Transfection efficiency was normalized by cotransfecting pRL-SV40 vector 
constitutively expressing Renilla luciferase. Cells were treated for 6 h. One-way ANOVA 
with p < 0.0025 and Dunnett’s multiple comparison test were applied; all samples were 
compared against the untreated control. Bars with (**) differ at p < 0.01. 
 
Figure 3: Vasoactive intestinal peptide (VIP) increases Star gene expression and 
steroidogenesis in primary mouse granulosa cells. Mature female CD-1 strain mice were 
stimulated with 8 IE pregnant mare serum gonadotropin (PMSG). After isolation cells were 
cultivated for 24h in culture medium and subsequently stimulated for 6 h in serum free media 
containing either 1mM dbcAMP or 1µM VIP. A) Progesterone production in the collected 
media was determined by radioimmunoassay B) Star mRNA expression as determined by 
Real Time (TaqMan) PCR normalised against the GAPDH. One-way ANOVA with p < 
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0.0001 (A,B) followed by Dunnett’s multiple comparison test was applied; all samples were 
compared against the untreated control. (**) indicates p < 0.01. 
 
Figure 4: Time course of vasoactive intestinal peptide (VIP)– induced PKA, CREB and 
cJUN activation in immortalized KK1 mouse granulosa cells. The KK1 cells were incubated 
in the presence of 1µM VIP for the times indicated. A) The effect of 1µM VIP on PKA 
activity in cultured KK1 cells over a period of 4 h. One-way ANOVA with p < 0.0001 and 
Dunnett’s multiple comparison test were applied; all samples were compared against the 
control. (**) indicates p < 0.01. B) Representative immunoblots using antibodies against total 
and phospho (P)- CREB (43 kDa) and (P)- cJUN (48 kDa). The lower panels show the 
densitometric values (integrated optical density) normalized against the respective total- 
CREB and -cJUN. One-way ANOVA with p < 0.0001 (CREB; cJUN) followed by Dunnett’s 
multiple comparison test was applied; all samples were compared against the control 
indicating: 0’ min. vs 5’-120’ min p<0.01 and 0’ min vs. 180’ min p < 0.05 for P-cJUN and 0’ 
min vs. 10-240’ min p< 0.01 for P-CREB. C) KK1 cells were transfected with PathDetect 
cJUN trans-reporting system; 36h after transfection cells were treated with 1 µM VIP and/or 
1mM dbcAMP for additional 6 h and luciferase activity in the cell lysate was determined. 
Lower case letters are used to designate groups that differ significantly (p < 0.01) 
 
Figure 5: Role of PKA in vasoactive intestinal peptide (VIP) – mediated STAR expression 
and steroidogenesis in immortalized KK1 mouse granulosa cells. KK1 cells were treated for 6 
h with 1.0 µM VIP with or without 0.3 mM dbcAMP. PKA activity was blocked with H89 
(25 µM). Untreated cells were used as negative control. A) Star mRNA expression as 
determined by Real Time (TaqMan) PCR normalised against the GAPDH. B) STAR (30kDa), 
P-STAR (30 kDa) and GAPDH (37 kDa) levels were examined by Western blot analysis. The 
average integrated optical density (IOD) for STAR, normalized with GAPDH, is shown as 
fold changes relative to the untreated control. C) Progesterone production in the collected 
media was determined by radioimmunoassay. One-way ANOVA with p < 0.0001 (A,C) 
followed by Dunnett’s multiple comparison test was applied; all samples were compared 
against the untreated control. Bars with (**) differ at p < 0.01. 
 
Figure 6: Role of PKC in vasoactive intestinal peptide (VIP) – mediated STAR expression 
and steroidogenesis in immortalized KK1 mouse granulosa cells. KK1 cells were treated as 
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indicated for 6h. GFX (20µM) was used to specifically block the PKC activity. Untreated 
cells and cells treated with 0.3 mM dbcAMP were used as controls. A) Star mRNA 
expression as determined by Real Time (TaqMan) PCR normalized against the GAPDH. B) 
STAR (30kDa), P-STAR (30 kDa) and GAPDH (37 kDa) levels were examined by Western 
blot analysis. The average integrated optical density (IOD) for STAR, normalized with 
GAPDH, is shown as fold changes relative to the untreated control. C) Progesterone 
production was determined by radioimmunoassay. One-way ANOVA with p < 0.0001 (A,C) 
followed by Dunnett’s multiple comparison test was applied; all samples were compared 
against the untreated control. Bars with (**) differ at p < 0.01. 
 
Figure 7: The induction of STAR phosphorylation in response to vasoactive intestinal peptide 
(VIP). KK1 cells were treated for 6 h with either 0.1 µM or 1.0 µM VIP with or without type 
II PKA analogs (25 µm MBC-cAMP together with 100µM PIP-cAMP) and PMA (20 nM). 
Untreated cells and cells treated with 0.3 mM dbcAMP were used as controls. A) Star mRNA 
expression as determined by Real Time (TaqMan) PCR normalised against the GAPDH. B) 
STAR (30kDa), P-STAR (30 kDa) and GAPDH (37 kDa) levels were examined by Western 
blot analysis. The average integrated optical density (IOD) for STAR, normalized with 
GAPDH, is shown as fold changes relative to the untreated control. C) Progesterone 
production was determined by radioimmunoassay. One-way ANOVA with p < 0.0001 (A,C) 
followed by Dunnett’s multiple comparison test was applied; all samples were compared 
against the untreated control. Bars with (**) differ at p < 0.01. 
  
 
Figure 8: The role of Vasoactive Intestinal Peptide (VIP) in regulating STAR. VIP-mediated 
induction of PKC and type I PKA can induce StAR expression but results only in weak P-
STAR and hence lower steroidogenic response. However, together with selective type II PKA 
activators, VIP increases P-STAR and enhances progesterone output.  
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